Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04265872
Title Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Baylor Research Institute

triple-receptor negative breast cancer


Bortezomib + Cisplatin + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center Recruiting Dallas Texas 75246 United States Details
*Shaded cells indicate that there was no data available from for the field